| 0.82 -0.012 (-1.39%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.22 | 1-year : | 1.4 |
| Resists | First : | 1.04 | Second : | 1.2 |
| Pivot price | 0.92  |
|||
| Supports | First : | 0.8 | Second : | 0.66 |
| MAs | MA(5) : | 0.85 |
MA(20) : | 0.97 |
| MA(100) : | 1.08 |
MA(250) : | 1.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.5  |
D(3) : | 4.4 |
| RSI | RSI(14): 14.6 |
|||
| 52-week | High : | 1.64 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IRIX ] has closed above bottom band by 14.0%. Bollinger Bands are 38.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.89 - 0.89 | 0.89 - 0.9 |
| Low: | 0.79 - 0.8 | 0.8 - 0.81 |
| Close: | 0.81 - 0.83 | 0.83 - 0.84 |
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
Fri, 31 Jul 2026
IRIX|IRIDEX Corp|Price:0.812|Chg%:-0.052 - TradingKey
Thu, 30 Jul 2026
IRIDEX Corporation Revenue Breakdown – BOATS:IRIX - TradingView
Wed, 29 Jul 2026
IRIX Faces Continued Pressure Near Key Support Levels – IRIDEX Corporation (IRIX) at $0.86 - Price Momentum Stocks - dars.gov.et
Tue, 28 Jul 2026
IRIX|IRIDEX Corp|Price:0.862|Chg%:-0.019 - TradingKey
Mon, 20 Jul 2026
Iridex Expands EyeProGPO Offering to Include EndoProbe Handpieces - Quiver Quantitative
Mon, 20 Jul 2026
More Than 4,300 EyeProGPO Members Gain Preferred EndoProbe Pricing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 17 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 37 (%) |
| Held by Institutions | 18.1 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 22 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | -6.3 % |
| Operating Margin | -2.8 % |
| Return on Assets (ttm) | -5.4 % |
| Return on Equity (ttm) | -56.6 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 1.08 |
| Sales Per Share | 3.02 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -4.32 |
| PEG Ratio | 0.9 |
| Price to Book value | -11.72 |
| Price to Sales | 0.27 |
| Price to Cash Flow | -6.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|